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AbstrAct
FBXW7 is a component of SCF (complex of SKP1, CUL1 and F-box-protein)-
type ubiquitin ligases that targets several oncoproteins for ubiquitination and 
degradation by the proteasome. FBXW7 regulates cellular apoptosis by targeting 
MCL1 for ubiquitination. Recently, we identified PLK1 as a new substrate of FBXW7 
modulating the intra-S-phase DNA-damage checkpoint. Taxanes are frequently used 
in breast cancer treatments, but the acquisition of resistance makes these treatments 
ineffective. We investigated the role of FBXW7 and their substrates MCL1 and PLK1 
in regulating the apoptotic response to paclitaxel treatment in breast cancer cells 
and their expression in breast cancer tissues. Paclitaxel-sensitive MDA-MB-468 and 
a paclitaxel-resistant MDA-MB-468R subclone were used to study the role of FBXW7 
and substrates in paclitaxel-induced apoptosis. Forced expression of FBXW7 or 
downregulation of MCL1 or PLK1 restored sensitivity to paclitaxel in MDA-MB-468R 
cells. By contrary, FBXW7-silenced MDA-MB-468 cells became resistant to paclitaxel. 
The expression of FBXW7 and substrates were studied in 296 invasive carcinomas by 
immunohistochemistry and disease-free survival was analyzed in a subset of patients 
treated with paclitaxel. In breast cancer tissues, loss of FBXW7 correlated with 
adverse prognosis markers and loss of FBXW7 and MCL1 or PLK1 accumulation were 
associated with diminished disease-free survival in paclitaxel-treated patients. We 
conclude that FBXW7 regulates the response to paclitaxel by targeting MCL1 and PLK1 
in breast cancer cells and thus targeting these substrates may be a valuable adjunct 
for paclitaxel treatment. Also, FBXW7, MCL1 and PLK1 may be relevant predictive 
markers of tumor progression and response to paclitaxel treatment.
INtrODUctION
FBXW7 is the F-box protein of the SKP1-CUL1-
FBXW7 (SCFFBXW7) E3 ubiquitin ligase, responsible 
for recruiting specific substrates for ubiquitination and 
degradation by the proteasome [1]. FBXW7 comprises 
three alternatively spliced isoforms, FBXW7 α, β and γ, 
of which FBXW7α is the predominant nuclear isoform in 
mammals [2]. Because many of the substrates that FBXW7 
targets for degradation are well-known oncoproteins, 
such as Cyclin E, c-Myc, Aurora kinase A (AURKA) 
and Notch-1, FBXW7 is generally accepted as a tumor 
suppressor [3, 4]. FBXW7 is frequently inactivated by 
deletion, mutation or promoter hypermethylation in 
multiple neoplasias. Inactivating mutations have been 
most frequently found in cholangiocarcinoma, T-cell 
acute lymphocytic leukemia, and carcinomas of colon, 
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endometrium and stomach [5]. In breast cancer, FBXW7 
promoter hypermethylation has been identified in 51% 
of a series of primary tumors [6]. Many of the primary 
tumors with FBXW7 mutations exhibit elevated levels 
of Cyclin E leading to deregulation of the cell cycle [7, 
8]. Loss of expression of FBXW7 has been reported 
in a series of breast carcinomas where Cyclin E was 
upregulated and associated with poor prognosis [9] but its 
relationship with other substrates has not been addressed. 
Other substrates such as c-Myc and AURKA have 
important roles in tumorigenesis by promoting cancer 
cell survival and migration [10-13] and AURKA has been 
found overexpressed in a series of triple negative breast 
carcinomas [14]. 
Paclitaxel is a microtubule polymerizing agent 
that blocks mitotic progression by activating the spindle 
assembly checkpoint and either causes cell death in mitosis 
by apoptosis or cells exit mitosis into a tetraploid G1 state, 
a process known as slippage [15]. Paclitaxel improves 
overall and disease-free survival in combination with 
anthracyclines or alkylating agents in metastatic and early 
stage breast cancer, although after the initial response, 
resistance to paclitaxel frequently ensues [16]. Several 
mechanisms for paclitaxel resistance in breast cancer have 
been reported including alterations in apoptotic pathways 
[17]. In fact, we reported that resistance to paclitaxel-
induced apoptosis in MDA-MB-231breast cancer cells is 
related to the inability to disrupt the interaction between 
BCL-xL, an anti-apoptotic BCL-2 family protein, and 
BAK; and BCL-xL accumulation may be of prognostic 
value in paclitaxel-treated patients [18]. Defective 
degradation and accumulation of related proteins may 
underlie the acquisition of resistance. MCL1, a pro-
survival BCL-2 family member that inhibits apoptosis by 
blocking the cell death mediators BAX and BAK [19], is 
targeted by FBXW7 for degradation upon phosphorylation 
by glycogen synthase kinase 3-beta (GSK3β) [20]. During 
anti-tubulin-induced mitotic arrest, MCL1 levels decline 
to potentiate cell death. Loss or inactivation of FBXW7 
conferred resistance to anti-tubulin agents paclitaxel and 
vincristine by blocking proteasomal degradation of MCL1 
[21]. We also identified this important role of MCL1 in 
preventing cell death during mitosis in prostate cancer 
cells after paclitaxel treatment [22]. Polo-like kinase 1 
(PLK1) is a major mitotic kinase that plays a key role in 
the division of eukaryotic cells [23]. PLK1 is recruited 
in metaphase by several proteins such as the spindle 
checkpoint component BubR1 [24], which inhibits Cdc20 
to prevent the activation of the anaphase promoting 
complex/cyclosome (APC/C). During late anaphase, 
PLK1 is degraded by APC/C-proteasome to properly 
control the exit from mitosis and cytokinesis [25]. PLK1-
depleted cells are arrested in prometaphase when the 
spindle checkpoint is activated, but these cells fail to 
arrest if MAD2 or BubR1 are co-depleted [26]. PLK1 is 
also implicated in the replication machinery [27]. In fact, 
we have recently reported that PLK1 is ubiquitinated and 
degraded by SCFFBXW7α/proteasome to modulate the intra-
S-phase checkpoint, where PLK1 plays an important role 
in the regulation of DNA replication by contributing to the 
formation of pre-replicative complexes [28]. 
Knowledge of paclitaxel resistance mechanisms 
will allow the identification of predictive tumor markers 
and therapeutic targets. Herein, we investigate the role of 
FBXW7 and relevant substrates in regulating apoptosis 
induced by paclitaxel in breast cancer cells, their 
expression in breast cancer tissues, and their potential 
predictive value in paclitaxel-treated patients. 
rEsULts
Expression of FbXW7 and its substrates in breast 
cancer cell lines
We selected hormone-dependent MCF7, T47D, 
and hormone-independent MDA-MB-231, MDA-
MB-468 breast cancer cell lines to study the expression 
levels of FBXW7 and its substrates by western blot in 
basal conditions (Figure 1A). FBXW7 protein levels in 
MCF7, and MDA-MB-468 cells were higher than those in 
T47D, and MDA-MB-231 cells. Accordingly, high levels 
of FBXW7 correlated with low levels of its substrates. 
Similar results were also observed in BT474 and SKBR3 
cells (Supplementary Figure S1). To confirm these results 
we silenced the expression of FBXW7 in MCF7 and 
MDA-MB-468 cells by using siRNA oligonucleotides. 
AURKA, c-Myc, Cyclin E, PLK1 and MCL1 levels all 
increased after FBXW7 downregulation in both cell lines 
(Figure 1B). MCF7 and MDA-MB-468 are sensitive to 
paclitaxel, so we generated paclitaxel-resistant MDA-MB-
468R cells by selecting survival clones after paclitaxel 
treatment of the MDA-MB-468 cell line. In order to 
investigate the potential role of FBXW7 in paclitaxel 
resistance, we compared FBXW7 protein levels of parental 
MDA-MB-468 cells (IC50 0.026 ± 0.004 µM) with those 
of paclitaxel-resistant MDA-MB-468R cells (IC50 0.183 
± 0.002 µM) (Figure 1C). In basal conditions, paclitaxel-
resistant MDA-MB-468R cells showed lower levels of 
FBXW7 and concordantly higher levels of AURKA, 
c-Myc, Cyclin E, PLK1 and MCL1 than paclitaxel-
sensitive MDA-MB-468 cells (Figure 1C), suggesting the 
involvement of FBXW7 in paclitaxel resistance. 
Paclitaxel-induced apoptosis and cell cycle 
analysis of MDA-Mb-468 and MDA-Mb-468r 
cells
Next, we examined paclitaxel-induced apoptosis 
in MDA-MB-468 and MDA-MB-468R cells by western 
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Figure 1: Expression of FbXW7 and its substrates in breast cancer cell lines. A. Western blot analyses of FBXW7, AURKA, 
c-Myc, Cyclin E, PLK1 and MCL1 in MCF7, T47D, MDA-MB-231 and MDA-MB-468 cells in basal conditions are shown, using β-actin 
as loading control. Quantifications of indicated proteins are shown as histograms and data are presented as mean ± SEM. b. Western blot 
analyses of MCF7 and MDA-MB-468 cells silenced with FBXW7 siRNA and with a nontargeting control are shown; β-actin was used to 
ensure equal loading. Histograms show the densitometric analyses of indicated proteins. Data are presented as mean ± SEM comparing 
siRNA control versus siRNA FBXW7 in MDA-MB-468 cells and siRNA control versus siRNA FBXW7 in MCF7 cells. *p < 0.05, **p 
< 0.01 and ***p < 0.001 from Student’s t-test. c. FBXW7, AURKA, c-Myc, Cyclin E, PLK1 and MCL1 were detected by Western blot 
in MDA-MB-468 and MDA-MB-468R cells in basal conditions. β-actin is shown as loading control. Densitometric analyses of indicated 
proteins are shown as histograms. Data are presented as mean ± SEM comparing MDA-MB-468 and MDA-MB-468R cells in basal 
conditions. *p < 0.05, **p < 0.01 and ***p < 0.001 from Student’s t-test. IC50 curves for paclitaxel in MDA-MB-468 (solid line) and 
MDA-MB-468R (dotted line) cell lines are shown. Data are presented as mean ± SEM.
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blot (Figure 2A). Cells were treated with 0.025µM 
paclitaxel and collected at 24 and 48 h. Cleavage of 
PARP, caspase-9 and caspase-3 were induced earlier 
and more potently in parental MDA-MB-468 cells than 
in MDA-MB-468R cells. Anti-apoptotic protein MCL1 
decreased after paclitaxel treatment in MDA-MB-468 
cells but not in MDA-MB-468R cells, in which MCL1 
remained unchanged. Paclitaxel treatment also induced 
the increase of Cyclin B1 and PTTG1 at 24 h in parental 
MDA-MB-468 cells and the later decrease of Cyclin B1, 
PTTG1, and BubR1 at 48 h to facilitate slippage and 
post-mitotic cell death. Mitotic exit is also reflected by 
the phospho-histone H3 (p-His H3) decrease at 48 h. In 
resistant MDA-MB-468R cells, Cyclin B1, PTTG1, and 
BubR1 increased after 24 h of paclitaxel treatment and 
did not fall at 48 h, p-His H3 also remained present, 
illustrating an association between slippage inhibition 
and impaired apoptosis in these cells. PLK1 needs to be 
degraded to allow mitotic progress and post-mitotic cell 
death. In sensitive MDA-MB-468 cells, PLK1 levels 
increased after 24 h of paclitaxel treatment and later 
decreased at 48 h. On the contrary, in paclitaxel treated 
MDA-MB-468R cells, high levels of PLK1 were still 
present at 48 h. Quantifications of western blot bands are 
shown in Supplementary Figure S2. We then analyzed the 
cell cycle and ploidy of paclitaxel-treated MDA-MB-468 
and MDA-MB-468R cells by flow cytometry and FISH. 
Paclitaxel treatment induced sensitive MDA-MB-468 cells 
to arrest in G2/M at 24 h and increased the sub-G0/G1 
apoptotic population at 48 h (Figure 2B). The cell cycle 
of resistant MDA-MB-468R cells was not affected after 
paclitaxel treatment at 24 h, but these cells showed a 
reduction of the G0/G1 population and fewer sub-G0/G1 
apoptotic events than parental cells at 48 h. In resistant 
cells, FISH analysis showed higher ploidy in DMSO than 
in MDA-MB-468 sensitive cells. As a result of slippage, 
cells duplicate their DNA without cytokinesis and increase 
ploidy. FISH analysis showed that 60% of paclitaxel-
treated MDA-MB-468 cells had higher than basal ploidy 
demonstrating slippage, whereas the percentage of ploidy 
remained unchanged in paclitaxel-treated MDA-MB-468R 
cells reflecting diminished slippage as a mechanism of 
paclitaxel resistance in these cells (Figure 2C). 
FbXW7 downregulation induces mitotic arrest 
and resistance to paclitaxel in MDA-Mb-468 cells
To gain insight into the implication of FBXW7 
in paclitaxel resistance, we investigated whether the 
downregulation of FBXW7 influenced the paclitaxel 
response of sensitive MDA-MB-468 cells. As shown in 
Figure 3A, interfering FBXW7 diminished the sensitivity 
to paclitaxel treatment as demonstrated by decreased 
levels of cleaved PARP, caspase-9 and caspase-3. Same 
results were also observed in MCF7 cells (Figure 3B), so 
to conclude they are not cell line specific. Flow-cytometric 
sub-G1 analysis was performed to confirm the results in 
MDA-MB-468 cells (Figure 3C). The accumulation of 
PTTG1, p-His H3 and Cyclin B1 illustrated mitotic arrest 
in paclitaxel-treated FBXW7-silenced MDA-MB-468, 
reinforcing the influence in mitotic arrest after FBXW7 
downregulation. We also confirmed increased protein 
levels of both FBXW7 substrates, MCL1 and PLK1. This 
further supports the importance of FBXW7 in achieving 
the complete paclitaxel response. Quantifications of 
western blot bands are shown in Supplementary Figure S3.
FbXW7 overexpression restores sensitivity to 
paclitaxel in resistant MDA-Mb-468r cells
To confirm our analysis, MDA-MB-468R cells were 
transiently transfected with pCMVHA-FBXW7 or the 
empty vector and treated with 0.025 µM paclitaxel during 
24 h. First, we examined the substrates of FBXW7 after 
transfection and treatment with paclitaxel (Figure 4A and 
Supplementary Figure S4A). AURKA, c-Myc, Cyclin E, 
PLK1, and MCL1 decreased after transfection of FBXW7 
in untreated cells. After paclitaxel treatment, the changes 
were most remarkable in PLK1, which accumulated in 
mock-transfected cells and was very low in FBXW7-
transfected cells, and MCL1, which dramatically reduced 
in the latter cell type. Next, we analyzed apoptosis and 
mitotic proteins in transfected cells after paclitaxel 
treatment (Figure 4B). Apoptosis was efficiently induced 
by paclitaxel in FBXW7-transfected MDA-MB-468R 
cells as shown by more cleavage of PARP, caspase-9 
and caspase-3. Flow-cytometric sub-G1 analysis also 
confirmed these results (Figure 4C). Cyclin B1, PTTG1, 
and BubR1 levels decreased after paclitaxel treatment in 
FBXW7-transfected cells (Figure 4B and Supplementary 
Figure S4B) and showed higher ploidy after FISH analysis 
(Supplementary Figure S4C), indicating that these cells 
recover the slippage mechanism to become sensitive to 
paclitaxel, similarly to the parental MDA-MB-468 cells. 
McL1 and PLK1 are major effectors of paclitaxel 
resistance in MDA-Mb-468r cells
We used siRNA oligonucleotides to study whether 
PLK1 or MCL1 downregulation may have major impact 
on the response to paclitaxel of resistant MDA-MB-468R 
cells. As expected, MCL1 downregulation increased 
apoptosis after 24 h of paclitaxel treatment in these cells as 
shown by increased levels of cleaved PARP, caspase-9 and 
caspase-3, therefore reverting their resistant phenotype 
(Figure 5A). Similarly, PLK1 downregulation was also 
able to promote paclitaxel-induced apoptosis efficiently 
in MDA-MB-468R cells (Figure 5B). Thus, we may 
conclude that MCL1 and PLK1 are contributors to the 
development of paclitaxel resistance in breast cancer cells.
Oncotarget52755www.impactjournals.com/oncotarget
Figure 2: Paclitaxel-induced apoptosis and cell cycle analysis of MDA-Mb-468 and MDA-Mb-468r cells. Cells were 
treated with 0.025 µM paclitaxel during 24 and 48 h. A. Intact and cleaved PARP, cleaved caspase-9 (CASP-9), cleaved caspase-3 (CASP-
3), MCL1, Cyclin B1, PTTG1, phospho-histone H3 (p-His H3), PLK1 and BubR1 proteins were detected by western blot. β-actin is shown 
as loading control. Densitometric analysis of cleaved PARP, cleaved CASP-9 and cleaved CASP-3 are shown as histograms. Data from 
triplicate experiments are presented as mean ± SEM comparing paclitaxel-treated MDA-MB-468 versus paclitaxel-treated MDA-MB-468R 
at 24 and 48 h. *p < 0.05 and ***p < 0.001 from Student’s t-test. b. Cell cycle analysis of propidium iodide-stained cells by flow cytometry. 
Quantification of each phase and sub-G1 cells are shown as histograms. c. Ploidy analysis by FISH. The number of signals per cells was 
determined for chromosomes 1, 11 and 17 in at least 100 cells. Representative photographs are shown. Histograms represent the percentage 
of cells with normal or higher ploidy for each condition.
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To analyze the relevance of each protein in slippage, 
we have analyzed Cyclin B1 and p-His H3 in PLK1-
silenced or MCL1-silenced MDA-MB-468R cells after 
treatment with DMSO or paclitaxel for 24h. In PLK1-
silenced cells paclitaxel treatment decreased CyclinB1 and 
p-His H3 after 24h while no differences were observed in 
paclitaxel-treated MCL1-silenced cells (Figure 5A-5B and 
Supplementary Figure S5). These results may indicate that 
PLK1 is more relevant for the regulation of slippage than 
MCL1 after paclitaxel treatment.
Figure 3: FbXW7 downregulation induces mitotic arrest and resistance to paclitaxel in MDA-Mb-468 and McF7 
cells. MDA-MB-468 A. and MCF7 b. cells were silenced with FBXW7 siRNA or with nontargeting control and treated with 0.025 
µM paclitaxel during 24 h. Expression levels of the indicated proteins were assessed by western blot, using β-actin as loading control. 
Densitometric analyses of cleaved PARP, cleaved caspase-9 (CASP-9) and cleaved caspase-3 (CASP-3) are shown as histograms. Data 
from triplicates are presented as mean ± SEM comparing paclitaxel-treated siRNA control versus paclitaxel-treated siRNA FBXW7. *p < 
0.05 from Student’s t-test. c. MDA-MB-468 cell cycle analysis of propidium iodide-stained cells by flow cytometry. Quantification of each 
phase and sub-G1 cells are shown as histograms and data from triplicates are presented as mean ± SEM. 
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Loss of FbXW7 correlates with substrate 
accumulation and adverse prognosis markers in 
breast cancer tissues
To analyze FBXW7 expression and its relation 
to the relative abundance of substrates, and with 
prognostic variables in breast cancer, we performed 
immunohistochemistry for FBXW7, AURKA, Cyclin 
E, MCL1 and PLK1 in tissue microarrays containing 
up to 296 samples of breast carcinomas. FBXW7 was 
present in nuclear location of 149 tumors (50.3%) and 
was diminished or absent in 147 tumors (49.7%). After 
characterizing all samples for their FBXW7 levels, 
we analyzed the correlation with clinicopathological 
variables (Table 1). Our data show that the loss of FBXW7 
expression correlated with adverse prognostic markers, 
e.g. high tumor grade, lack of hormone receptors or 
HER2 positivity. To further investigate whether FBXW7 
expression correlated with its substrates in breast cancer 
tissues, we decided to study the protein levels of Cyclin E, 
MCL1, AURKA and PLK1 in these samples (Figure 6). 
AURKA and MCL1 were located in the cytoplasm, Cyclin 
E showed a nuclear pattern and PLK1 cytoplasmic and 
nuclear location. FBXW7 showed a statistically significant 
correlation with the expression of Cyclin E, MCL1 and 
Figure 4: FbXW7 overexpression restores sensitivity to paclitaxel in resistant MDA-Mb-468r cells. Cells were transiently 
transfected with pCMVHA-FBXW7 or with empty vector and treated with 0.025 µM paclitaxel during 24 h. A. FBXW7, HA, AURKA, 
c-Myc, Cyclin E, PLK1 and MCL1 proteins were detected by western blot. β-actin is shown as loading control. b. Western blot analysis 
of cleaved PARP, cleaved caspase-9 (CASP-9) and cleaved caspase-3 (CASP-3) is shown; β-actin was used to ensure equal loading. 
Densitometric analyses of cleaved PARP, cleaved CASP-9 and cleaved CASP-3 are shown as histograms. Data from triplicates are presented 
as mean ± SEM comparing paclitaxel-treated empty vector versus paclitaxel-treated HA-FBXW7. *p < 0.05 from Student’s t-test. c. Cell 
cycle analysis of propidium iodide-stained cells by flow cytometry. Quantification of each phase and sub-G1 cells are shown as histograms.
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Figure 5: silencing PLK1 or McL1 restores sensitivity to paclitaxel in resistant MDA-Mb-468r cells. Cells were silenced 
A. with siRNA MCL1 or b. with siRNA PLK1 or with nontargeting controls and treated with 0.025 µM paclitaxel during 24 h. Apoptosis 
induction was measured by appearance of cleaved PARP, cleaved caspase-9 (CASP-9) and cleaved caspase-3 (CASP-3) by western blot. 
MCL1, PLK1, Cyclin B1 and p-His H3 were also assessed by western blot, using β-actin as a loading control. Densitometric analysis of 
cleaved PARP, cleaved caspase-9 (CASP-9) and cleaved caspase-3 (CASP-3) are shown as histograms. Data from triplicates are presented 
as mean ± SEM comparing paclitaxel-treated siRNA control versus paclitaxel-treated siRNA MCL1 or siRNA PLK1. *p < 0.05 and **p < 
0.01 from Student’s t-test.
Figure 6: Immunohistochemical expression of FbXW7 and substrates in breast carcinomas. Representative micrographs 
of FBXW7, Cyclin E, AURKA, MCL1 and PLK1 in breast carcinomas, tumor grade 1 to 3 (top to bottom), are shown. Scale bars, 100 µm.
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PLK1, and the expression levels of these three proteins 
increased concordantly in high grade tumors. 
Immunohistochemical expression levels of 
FbXW7, McL1 and PLK1 in cancer patients are 
associated with paclitaxel therapy response
To assess the relationship between FBXW7, 
MCL1 and PLK1 expression and the response to 
chemotherapy in breast cancer, we performed an analysis 
of FBXW7, MCL1 and PLK1 expression in two groups 
of node-negative breast cancer patients treated with 
FEC (5-Fluorouracil, epirubicin, cyclophosphamide; n = 
41) or FEC with paclitaxel (FECP; n = 44). Diagnostic 
biopsies of breast cancer patients were analyzed by 
immunohistochemistry for the expression of FBXW7, 
MCL1 and PLK1. We performed Kaplan-Meier analyses 
and the disease free survival was evaluated in months as 
the time variable. With a mean follow up time of 113.9 
months after FEC treatment, disease progression was 
demonstrated in 30.0%, 25.0% and 20.7% patients with 
low FBXW7, MCL1 or PLK1 expression, respectively; 
and in 19%, 23.8% and 33.3% patients with high FBXW7, 
MCL1 or PLK1 expression. The mean time for achieving 
disease progression was 97.6 months, 118.9 months 
table 1:  FbXW7 expression in breast carcinomas and its relationship with clinicopathological 
variables and substrates.  
FbXW7 Low High p-valuea
Number (%) Number (%)










Node Negative 77 (52.4) 93 (62.4) 0.080
Positive 70 (47.6) 56 (37.6)


























































































ER, estrogen receptor; PR, progesterone receptor
 ap-values were obtained from χ2 test
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and 119.3 months in patients with low FBXW7, MCL1 
or PLK1-expressing tumors; and 122.9 months, 97.6 
months and 91.0 months in patients with high FBXW7, 
MCL1 or PLK1-expressing tumors. Kaplan-Meier 
curves were not significantly different (p = 0.241, p = 
0.670 and p = 0.192 from Mantel and Cox, log-rank test; 
χ2 = 1.377, χ2 = 0.182, χ2 = 1.7; 1 degree of freedom) 
between both groups for FBXW7, MCL1 and PLK1 
expression, respectively (Figure 7). In contrast, at the 
mean follow-up of 120.6 months post FECP treatment, 
disease progression was demonstrated in 55.5% patients 
with low FBXW7 expression, 6.25% patients with low 
MCL1 or PLK1 expression; and in 2.8% patients with 
high FBXW7 expression and in 33.3% patients with high 
MCL1 or PLK1 expression. The mean time for achieving 
disease progression was 82.5 months in patients with low 
FBXW7-expressing tumors, and 129.5 months in patients 
with high FBXW7-expressing tumors. Kaplan-Meier 
curves were significantly different (p <0.001 from Mantel 
and Cox, log-rank test; χ2 = 20.972; 1 degree of freedom) 
between both groups. The mean time for achieving disease 
progression was 127.3 months in patients with low MCL1 
or PLK1-expressing tumors and 101.2 months in patients 
with high MCL1 or PLK1-expressing tumors. Kaplan-
Meier curves were significantly different (p = 0.012 from 
Mantel and Cox, log-rank test; χ2 = 6.35; 1 degree of 
freedom) between both groups (Figure 7).
DIscUssION
FBXW7 acts as a tumor suppressor involved in 
the degradation of substrates with oncogenic activity 
frequently overexpressed in breast cancer such as Cyclin 
E, c-Myc and AURKA [14, 29-31]. It also controls 
degradation of MCL1 [20, 21], which has an important 
role in the regulation of apoptosis, and PLK1 [28], a 
protein kinase involved in essential events of the cell cycle 
[25, 32]. Treatment with taxanes improves survival of 
node-negative breast cancer patients [33], but acquisition 
of resistance can cause this treatment to lose effectivity 
[15, 17]. We sought to investigate the role of FBXW7 
in the response to paclitaxel in breast cancer cells and 
Figure 7: Expression levels of FbXW7, McL1 and PLK1 and association with disease-free survival (DFs) in 
paclitaxel-treated patients. Kaplan-Meier analysis of disease-free survival in patients treated with FEC (5-Fluorouracil, epirubicin and 
cyclophosphamide; left) and FECP (5-Fluorouracil, epirubicin, cyclophosphamide and paclitaxel; right) showing either high (dotted line) 
or low (solid line) expression of FBXW7, MCL1 and PLK1. Tick marks represent censored patients. The p values were obtained from the 
long-rank test of Mantel and Cox. 
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in patients with node-negative disease. Commonly 
used breast cancer cell lines have different responses to 
paclitaxel [18]. We chose basal-like phenotype, paclitaxel-
sensitive MDA-MB-468 cells that express abundant 
FBXW7 to study the role of this protein in mitotic arrest 
and apoptosis induced by paclitaxel, with special focus 
on the regulation of MCL1 and PLK1. We observed that 
paclitaxel-resistant subclonal MDA-MB-468R cells had 
lower levels of FBXW7 and accumulated PLK1 and 
MCL1 to impair mitosis progress and apoptosis after 
paclitaxel treatment. The silencing of FBXW7 in sensitive 
MDA-MB-468 and MCF7 cells induced the accumulation 
of both substrates and disabled apoptosis in response to 
paclitaxel. This prompted us to consider FBXW7 as an 
important mediator of the paclitaxel response through the 
control of MCL1 and PLK1 degradation in breast cancer. 
MCL1 is an anti-apoptotic protein involved in 
resistance to cancer therapies such as cisplatin in lung 
cancer [34] or rituximab in lymphomas [35, 36]. MCL1 
is also relevant in the response to anti-mitotic agents 
because cell death in mitosis may depend on MCL1 
phosphorylation by CDK1-Cyclin B1 complex and its 
subsequent degradation [37]. Wertz et al. showed that 
MCL1 was stabilized in FBXW7-deficient cells arrested 
in mitosis and that JNK/p38/CKII kinases were regulators 
of the MCL1 degradation. These authors also showed 
that sensitivity to anti-mitotic agents was regulated by 
FBXW7 through degradation of MCL1 in colon and 
ovarian cancer cells. We observed that resistant MDA-
MB-468R cells, which are FBXW7-deficient, arrest in 
mitosis after paclitaxel treatment but MCL1 levels remain 
high and apoptosis diminishes. This also occurred when 
FBXW7 mRNA is interfered in paclitaxel-sensitive 
MDA-MB-468 cells. Sensitivity to paclitaxel-induced 
apoptosis can be restored in resistant cells by either 
reintroducing FBXW7 expression or interfering MCL1. 
Furthermore, we demonstrated that PLK1 is also involved 
in paclitaxel resistance because decreasing the levels of 
PLK1 by siRNA sensitized resistant breast cancer cells 
to treatment with paclitaxel. In this sense, PLK1 levels 
have been related to improved sensitivity to paclitaxel and 
trastuzumab when combined with siRNA targeting PLK1 
in breast cancer cell lines in a synergistic way [38]. 
After anti-mitotic treatments, cells may die in 
mitosis, or may either undergo slippage and then die, stay 
in G0, or enter a new cell cycle with increased ploidy 
[15]. We observed that paclitaxel-sensitive MDA-MB-468 
cells die after slippage while paclitaxel-resistant MDA-
MB-468R cells survived, probably after slippage, and 
continued cycling into an aneuploid state. These results are 
in concordance with those of Finkin et al., who reported 
that FBXW7-deficient cells are more likely to escape 
mitosis after anti-mitotic treatments and accumulate 
genetic errors [39]. Whether mitotic slippage constitutes 
a cell survival strategy or a cell death mechanism is not 
yet well understood. Riffell et al. showed that reinforcing 
mitotic arrest with drugs that inhibit mitotic slippage can 
lead to increased cell survival and proliferation, whereas 
inducing mitotic slippage in cells treated with antimitotic 
drugs seems to lead to cell death [40]. We previously 
observed that slippage-prone PC3 cells suffered less 
efficient apoptosis when they were arrested in mitosis and 
MCL1 was not properly degraded [22]. Therefore, MCL1 
degradation has great importance in the balance between 
mitosis and apoptosis [41]. In this sense, the control of 
MCL1 degradation by FBXW7 seems determinant and we 
observed that FBXW7 transfection in paclitaxel resistant 
cells decreased the levels of MCL1 and restored sensitivity 
to apoptosis. Also, paclitaxel-resistant cells transfected 
with FBXW7 were prone to mitotic slippage as noted by 
the downregulation of Cyclin B1, PTTG1 and BubR1, and 
thus they recapitulated the behavior of paclitaxel-sensitive 
cells. 
We noticed that the paclitaxel-resistant subclone 
had aneuploid DNA content. This genetic instability 
could be related to FBXW7 loss as it contributes to the 
accumulation of Cyclin E, AURKA, BubR1 and PLK1. 
These findings are consistent with those reported by Finkin 
et al., where FBXW7-deficient cells showed aneuploidy 
associated with increased Cyclin E and AURKA, and that 
AURKA could mediate the induction of aneuploidy by the 
p53-LATS2 pathway [39]. Moreover, PLK1 contributes to 
SAC regulation [42], and components of the SAC, such 
as BubR1, are associated with chromosomal instability 
[43, 44]. Dysregulated activity of PLK1 results in 
abnormalities in microtubules and increased centrosome 
size and number, and both phenomena have been related to 
aneuploidy [45]. Therefore, FBXW7 could be contributing 
to increased genetic instability through the regulation of 
PLK1 since FBXW7-deficient cells have higher levels of 
PLK1. 
We show that paclitaxel resistant cells are aneuploid 
and accumulate MCL1 and PLK1 as well as in sensitive 
cells silenced for FBXW7. In cells silenced for FBXW7, 
paclitaxel treatment arrested cells more efficiently in 
mitosis, thus preventing the degradation of both substrates. 
These results point to the involvement of FBXW7 in the 
control of the degradation of these substrates in breast 
cancer cells and in response to apoptosis in cells arrested 
in mitosis. PLK1 needs to be degraded by the APC/CCDH1-
proteasome in late anaphase to adequately control the exit 
from mitosis and cytokinesis so that cells can enter in G1 
phase [25], but as we see in Figure 3, BubR1 is increased 
in cells silenced for FBXW7 so the SAC remains active. 
This could contribute to the inactivation of APC/Cdc20, 
thus preventing the degradation of PTTG1, Cyclin B1 
and PLK1. Elowe et al. demonstrated that diminished 
BubR1 contributes to cells escaping by slippage [24]. We 
observed a similar response in the paclitaxel sensitive 
cells, where BubR1 and PLK1 levels are low, and taxol 
treatment induced the cells to exit mitosis by slippage 
with subsequent apoptosis. Consistent with these 
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data, van Vugt et al. [26] established the role of PLK1 
in the control of mitosis by regulation of the spindle 
checkpoint. They showed that PLK1 depleted cells arrest 
in prometaphase with an activated spindle checkpoint, but 
if these cells are BubR1 co-depleted, they fail to arrest in 
mitosis. Accordingly, resistant cells and cells silenced for 
FBXW7 accumulate both proteins, particularly PLK1, an 
accumulation that remains after paclitaxel treatment and 
is accompanied by efficient mitotic arrest with less death 
by apoptosis. 
We also looked at the relative expression of FBXW7 
and its substrates in a series of breast carcinoma tissues 
to establish whether these proteins could be valuable 
prognostic markers and predict patient response to 
paclitaxel treatment. We observed that expression levels of 
FBXW7 correlated inversely with the levels of substrates 
in a statistically significant way with Cyclin E, PLK1 and 
MCL1. Ibusuki et al. previously reported that a decreased 
expression of FBXW7 was associated with increased 
levels of Cyclin E and c-Myc in a group of patients with 
breast carcinoma of a more aggressive tumor stage [9]. We 
see that loss of nuclear FBXW7 associates significantly 
with higher tumor size and grade and with HER2-positive 
and triple negative phenotypes. Our study also shows that 
loss of FBXW7 and increased levels of MCL1 and PLK1 
are associated with lower disease-free survival in patients 
whose treatment includes paclitaxel. We conclude that 
FBXW7 can be a marker of prognostic value and that the 
patient’s response to paclitaxel is most effective in slowing 
disease progression when FBXW7 is present and MCL1 
and PLK1 do not accumulate.
In summary, we show that FBXW7 plays a 
prominent role in paclitaxel-induced apoptosis by 
regulating MCL1 and PLK1 levels in breast cancer, 
as resistant cells loose FBXW7 and accumulate these 
substrates. Loss of FBXW7 is associated with adverse 
prognostic factors such as tumor grade or non-luminal 
phenotypes and FBXW7, MCL1 and PLK1 levels may 
have predictive value in patients treated with paclitaxel. 
Reintroducing FBXW7 activity or interfering MCL1 and 
PLK1 restores paclitaxel sensitivity in resistant cells and 
thus, targeting these substrates may be a valuable adjunct 
to paclitaxel for the treatment of breast cancer. Notably, 
for the first time, we observed a direct association between 
FBXW7 and PLK1 expression in breast cancer tissues. 
MAtErIALs AND MEtHODs
cell culture
MCF7, T47D, MDA-MB-231, MDA-MB-468, 
SKBR3 and BT474 breast cancer cell lines from the 
Interlab Cell Line Collection (Genoa, Italy) were routinely 
grown in RPMI 1640 supplemented with 10% fetal bovine 
serum, 50 U/mL penicillin, 50 µg/mL streptomycin, 10 
mmol/L HEPES buffer and 1 mM glutamine in a 37ºC 
humidified incubator under 5% CO2. Subconfluent 
cell cultures were harvested by trypsinization. All the 
experiments were performed using cells that had not 
exceeded the first ten passages after receipt of the initial 
vial. Stock solution of paclitaxel (Calbiochem) was 
prepared at 10 mM in dimethyl sulfoxide (DMSO, Sigma) 
and stored frozen. In all the experiments, DMSO was 
added to untreated cells. The paclitaxel-resistant MDA-
MB-468R cell line was generated in our laboratory as 
follows. Parental MDA-MB-468 cells were treated with 4 
nM paclitaxel for 2 months; then, the concentration of the 
drug in the medium was reduced by half. The surviving 
cells were maintained with 1 nM paclitaxel for 1 month 
and finally, the drug was withdrawn from the medium. The 
surviving cells were again subjected to the same treatment 
and the resulting paclitaxel-resistant cells were used for 
the assays.
small interfering rNA (sirNA) and plasmid 
transfections
Validated pools of FBXW7α-, MCL1-, PLK1-
siRNA and non-targeting siRNA as negative control 
were obtained from GE Dharmacon (ON-TARGETplus 
SMART pools L-004264, L-004501, L-003290, and 
D-001810). Transfections were carried out using 
DharmaFECT 2 reagent (GE Dharmacon) according to 
manufacturer’s instructions. All siRNA pools were used 
at 50 nM. Cells were subjected to different treatments 24 
h after silencing. Transient transfections of pCMVHA and 
pCMVHA-FBXW7 plasmids [28] were carried out using 
FuGENE reagent (Promega) according to manufacturer’s 
instructions. Cells were subjected to different treatments 
24 h after transfection.
Antibodies
 The antibodies and dilutions used for western 
blots were as follows: rabbit polyclonal anti-FBXW7 
(1:500) and anti-AURKA (1:2,000) from Novus; rabbit 
polyclonal anti-MCL1 (S-19, 1:1,000), anti-Cyclin B1 
(1:1,000), anti-phospho-histone H3 (Ser10, 1:500) and 
mouse monoclonal anti-PTTG1 (1:1,000) from Santa 
Cruz; mouse monoclonal anti-β-actin (Ac15, 1:20,000) 
and rabbit polyclonal anti-c-Myc (1:1,000) from Sigma; 
rabbit polyclonal anti-cleaved caspase-9 (Asp 315, 
1:500), anti-cleaved caspase-3 (Asp 175, 1:500) from 
Cell Signaling; rabbit polyclonal anti-BubR1 (1:3,000) 
from Bethyl; mouse monoclonal anti-PARP (1:500) from 
BD Bioscience; mouse monoclonal anti-Cyclin E (1:500) 
from Monosan; mouse monoclonal anti-PLK1 (1:10,000) 
from Millipore, and rat monoclonal anti-HA-peroxidase 
(50 mU/mL) from Roche. For immunohistochemical 
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analyses, anti- FBXW7 (1:2,000), anti- Cyclin E (1:100), 
anti- MCL1 (1:1,250), anti-AURKA (1:700), and anti-
PLK1 (1:1,000) were used.
Western blotting
Cells were lysed in Nonidet P-40 (NP40) lysis buffer 
[10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10% glycerol, 
and 1% NP40]. Twenty micrograms of total protein, as 
determined by the BCA protein assay kit (Pierce), were 
separated by SDS-PAGE on 8% polyacrylamide gels 
and electroblotted onto nitrocellulose membranes (GE 
Healthcare). Membranes were stained with Ponceau 
S to ensure that protein amounts were comparable. For 
immunodetection, blots were blocked in 1% blocking 
reagent (Roche) in 0.05% Tween 20-phosphate buffered 
saline (PBS) for 1 hour and incubated with primary 
antibody diluted in blocking buffer overnight at 4ºC. 
Blots were then washed in 0.05% Tween 20-PBS and 
incubated with either goat anti-mouse (1:20,000; GE 
Healthcare) or goat anti-rabbit (1:20,000; GE Healthcare) 
peroxidase-labeled antibodies in blocking buffer for 
1 hour. The enhanced chemoluminescent system was 
applied according to the manufacturer’s protocol (GE 
Healthcare). The experiments were performed at least 
three times and densitometric analysis was performed 
using ImageJ software (http://imagej.nih.gov/ij/). Arbitrary 
densitometric units of the proteins of interest were 
corrected for those of β-actin. Data comparing differences 
between the two conditions were statistically analyzed, 
when indicated, using paired Student’s t-test. Statistical 
analyses were performed with Prism 4.0 software 
(GraphPad). Differences were considered as significant 
when p < 0.05.
Flow cytometric analysis of cell cycle
Cells were trypsinized and fixed in 70% ethanol. 
Propidium iodide staining of nuclei was performed with a 
CycleTest Plus DNA reagent kit (BD Biosciences), and the 
DNA content was measured with a FACScan instrument 
(BD Biosciences). Data were acquired with CellQuest Pro 
software (BD Biosciences). 
Fluorescence in situ hybridization (FIsH)
Cultured cells were imprinted onto silanized slides, 
fixed in ice-cold methanol/glacial acetic acid (3:1) for 
10 min and air-dried. Then, slides were immersed in 
a 2x SSC/0.3% NP40 solution at 37ºC during 30 min, 
dehydrated in an increasing series of graded ethanols 
and air-dried. Cellular DNA and centromeric probes for 
chromosomes 8 (Spectrum red), 11 (Spectrum green) and 
17 (Spectrum aqua) from Vysis were co-denatured at 72ºC 
for 5 min and hybridized at 37ºC overnight in a humid 
chamber (Thermomixer, Eppendorf). After hybridization, 
slides were washed in 2x SSC/0.3% NP40 solution at 72ºC 
for 5 min, counterstained, mounted with DAPI/antifade 
solution (Vysis), and visualized under fluorescence 
microscopy equipped with appropriate filter sets and a 
digital camera (Leica). At least one hundred cells were 
counted to calculate the percentage of cells with normal 
ploidy and higher ploidy in each condition.
cytotoxicity assay
6 x 103 cells/well in exponential cell growth were 
plated in 96-well plates (Nunc). Following cell adherence 
(growth for 24 h), experimental medium containing 
paclitaxel was added to triplicate wells, and serial 
dilutions were performed to span the dose range suitable 
for the analysis. Cells were exposed to the drug for 72 h 
and a cell viability assay was performed using alamarBlue 
Cell Viability Assay Reagent (Thermo Scientific) 
according to manufacturer’s instructions. Fluorescence 
was measured with excitation wavelength at 545 nm and 
emission wavelength at 590 nm with FLx800 Microplate 
Fluorescence Reader (Bio-Tek). Data were normalized to 
vehicle treatment, and the half inhibitory concentrations 
(IC50) were calculated using OriginPro 8 and Prism 4.0 
software (GraphPad). The experiments were performed at 
least three times.
Immunohistochemical staining and scoring
Formalin-fixed, paraffin-embedded tissue blocks 
from 296 patients with invasive breast carcinoma were 
selected to build up tissue microarrays with 1 mm cores. 
The study was approved by the Ethical Committee of 
the hospital. Five µm tissue sections were dewaxed, 
rehydrated, and immersed in 3% H2O2 aqueous solution 
for 30 minutes to exhaust endogenous peroxidase. 
Heat-induced epitope retrieval was performed with 1 
mM EDTA (pH 9.0) in a microwave oven. Sections 
were incubated overnight at 4ºC with the primary 
antibodies. Peroxidase-labeled secondary antibodies 
and 3,3’-diaminobenzidine were applied according to 
manufacturer’s protocol (EnVision, Dako). Slides were 
then counterstained with hematoxylin and mounted. 
Sections where the primary antibody was omitted were 
used as negative controls. Immunostains were scored as 
low (<25%) or high expression (≥25%) according to the 
extent of positive cells. Correlations between proteins 
and clinicopathological variables were analysed by χ2 test 
using Prism 4.0 software (GraphPad). Differences were 
considered as significant when p < 0.05. The association 
of FBXW7, MCL1 and PLK1with paclitaxel therapy 
response was analyzed by the method of Kaplan-Meier.
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Abbreviations
DAPI, 4´,6-Diamidino-2-phenyl-indole; DMSO, 
Dimethyl sulfoxide; NP40, Nonidet-P40; PARP, Poly 
(ADP-ribose) polymerase.
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